Photo by nci from unsplash
e20529Background: Exclusion from cancer clinical trials is common for patients taking QTc-interval prolonging drugs. To estimate the potential impact on accrual, we determined the prevalence of QTc... Click to show full abstract
e20529Background: Exclusion from cancer clinical trials is common for patients taking QTc-interval prolonging drugs. To estimate the potential impact on accrual, we determined the prevalence of QTc...
Keywords:
prolonging medications;
clinical trials;
cancer;
qtc prolonging;
use qtc;
medications among
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!